Physician profile
Cyril E Severns
NPI 1013904176
$949.78
in general payments reported to CMS, 2019-2025
14 companies · $24.33 in 2025
The $24.33 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141 · 2021: $66.36 · 2023: $576 · 2024: $143 · 2025: $24.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $743.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $742.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $256.38 | 2021-2024 | Skyrizi, Humira |
| Lilly USA, LLC | $159.33 | 2021-2024 | Taltz, Olumiant |
| Genzyme Corporation | $123.81 | 2019 | |
| Organogenesis INC. | $99.34 | 2023-2025 | Puraply, Matrix, Via Matrix |
| Leo Pharma INC. | $66.75 | 2021-2023 | Adbry |
| Dermavant Sciences, INC. | $47.87 | 2023 | Vtama |
| Sun Pharmaceutical Industries INC. | $41.87 | 2023-2024 | Odomzo, Blu-U |
| Janssen Biotech, INC. | $34.05 | 2023 | Tremfya |
| Ucb, INC. | $27.36 | 2023-2024 | Bimzelx |
| Kyowa Kirin, INC. | $25.78 | 2023 | Poteligeo |
| Biofrontera INC. | $18.97 | 2023-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Incyte Corporation | $17.58 | 2023 | Opzelura |
| Dusa Pharmaceuticals, INC. | $16.90 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $13.79 | 2024 | Jublia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cyril Severns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.